BioCentury | Feb 4, 2020
Finance

Feb. 4 Financial Quick Takes: Catalent raises $500M; venture rounds for BenchSci, Lightship, Inato

...series A round led by Obvious Ventures and Cathay Innovation with participation by existing investors Serena...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cardiovascular

...DETAILS: Zacchigna, S. et al. Nat. Commun. ; published online June 26, 2018 doi:10.1038/s41467-018-04908-z CONTACT: Serena...
BioCentury | Jul 5, 2010
Finance

2Q approvals

...to treat Huntington's disease (HD) Newron Pharmaceuticals S.p.A. (SIX:NWRN) Ralfinamide fails in the Phase IIb/III SERENA...
BioCentury | May 10, 2010
Finance

Regulatory milestones

...59%) to CHF7.99 on Thursday after ralfinamide missed the primary endpoint in the Phase IIb/III SERENA...
BioCentury | May 10, 2010
Analyst Picks & Changes

Analyst picks & changes

...SERENA trial to treat neuropathic low back pain (see B16). He expects additional data from SERENA...
BioCentury | May 10, 2010
Clinical News

Ralfinamide: Phase IIb/III data

...Top-line data from the double-blind, international Phase IIb/III SERENA trial in 411 patients showed that ralfinamide...
BioCentury | May 7, 2010
Clinical News

Ralfinamide misses back pain endpoint

...59%) to CHF7.99 on Thursday after ralfinamide missed the primary endpoint in the Phase IIb/III SERENA...
BioCentury | Jan 18, 2010
Clinical News

Ralfinamide: Completed Phase IIb/III enrollment

...Newron completed enrollment of 411 patients in the double-blind, international Phase IIb/III SERENA trial comparing 160...
BioCentury | Apr 6, 2009
Clinical News

Ralfinamide: Phase IIb/III started

...Newron began the 12-week, double-blind, international Phase IIb/III SERENA trial to compare 160 and 320 mg...
Items per page:
1 - 9 of 9
BioCentury | Feb 4, 2020
Finance

Feb. 4 Financial Quick Takes: Catalent raises $500M; venture rounds for BenchSci, Lightship, Inato

...series A round led by Obvious Ventures and Cathay Innovation with participation by existing investors Serena...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cardiovascular

...DETAILS: Zacchigna, S. et al. Nat. Commun. ; published online June 26, 2018 doi:10.1038/s41467-018-04908-z CONTACT: Serena...
BioCentury | Jul 5, 2010
Finance

2Q approvals

...to treat Huntington's disease (HD) Newron Pharmaceuticals S.p.A. (SIX:NWRN) Ralfinamide fails in the Phase IIb/III SERENA...
BioCentury | May 10, 2010
Finance

Regulatory milestones

...59%) to CHF7.99 on Thursday after ralfinamide missed the primary endpoint in the Phase IIb/III SERENA...
BioCentury | May 10, 2010
Analyst Picks & Changes

Analyst picks & changes

...SERENA trial to treat neuropathic low back pain (see B16). He expects additional data from SERENA...
BioCentury | May 10, 2010
Clinical News

Ralfinamide: Phase IIb/III data

...Top-line data from the double-blind, international Phase IIb/III SERENA trial in 411 patients showed that ralfinamide...
BioCentury | May 7, 2010
Clinical News

Ralfinamide misses back pain endpoint

...59%) to CHF7.99 on Thursday after ralfinamide missed the primary endpoint in the Phase IIb/III SERENA...
BioCentury | Jan 18, 2010
Clinical News

Ralfinamide: Completed Phase IIb/III enrollment

...Newron completed enrollment of 411 patients in the double-blind, international Phase IIb/III SERENA trial comparing 160...
BioCentury | Apr 6, 2009
Clinical News

Ralfinamide: Phase IIb/III started

...Newron began the 12-week, double-blind, international Phase IIb/III SERENA trial to compare 160 and 320 mg...
Items per page:
1 - 9 of 9